Objectives: Although several antiretroviral drugs, including the d-drugs stavudine (d4T) and didanosine (ddI), may cause biomarker-defined hepatotoxicity, their association with clinically defined end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC) remains unknown.
Introduction
The majority of the antiretroviral drug classes used for the treatment of HIV have an intrinsic potential to cause hepatotoxicity, which may be induced through various mechanisms [1] [2] [3] [4] . Previous studies have estimated that up to 30% of all HIV-positive persons will experience some form of hepatotoxicity associated with antiretroviral treatment (ART) [1] [2] [3] . Studies that have investigated adverse ART-liver effects have commonly been based on changes in liver-related biomarkers such as transaminases [3, [5] [6] [7] [8] [9] , fibrosis markers (e.g., hyaluronic acid) [10] , imaging modalities or biopsy findings [11] [12] [13] [14] [15] [16] [17] . Furthermore, most studies have been of a relatively modest size or of a cross-sectional nature, making assessments of the time course between exposure and outcomes difficult [13] [14] [15] [16] [17] [18] [19] . Studies have also been primarily conducted among individuals who are coinfected with HIV and viral hepatitis, in whom the incidence of adverse hepatic impairment is elevated compared with HIV monoinfected individuals [5, 14, 18, 20, 21] . Indeed, a previous data collection on adverse events of anti-HIV drugs (D:A:D) study analysis in participant without viral hepatitis found that deaths related to liver failure are rare in HIV-positive individuals without viral hepatitis B (HBV) or C (HCV) [20] .
The adverse effects of ART on development of liver impairment have been debated for years [20, [22] [23] [24] [25] . The diverse study outcomes are, however, not surprising as these will naturally depend on the individual antiretroviral investigated. ART is known to have an overall beneficial effect on liver-related outcomes, largely because of attenuating liver disease progression in viral hepatitis coinfected individuals by improvements in immune function [22, 24] , and the direct antiviral effect on HBV by certain individual antiretrovirals such as tenofovir (TDF), lamivudine (3TC) and emtricitabine (FTC) . Conversely, other antiretrovirals, such as tipranavir (TPV), have a known direct hepatotoxic effect [4] . Furthermore, an excess risk of liver-related death with cumulative ART use has been observed after accounting for improvements in the CD4 þ cell count [24, 26] .
Among the individual antiretrovirals, dideoxynucleoside analogues or 'd-drugs ' and, in particular, didanosine (ddI) and stavudine (d4T) have commonly been associated with alterations in liver function and severe steatosis/fibrosis development [11, 13, 16, 17, [27] [28] [29] [30] [31] . Moreover, ddI use has been linked with development of noncirrhotic portal hypertension [32, 33] . Use of d-drugs is now rare in most high-income countries because of their serious adverse effects including neuropathy and lipodystrophy [4] . D-drug use was, however, common in the past, and previous exposure may also impact on subsequent liver function [34] . In 2010, the WHO launched an initiative aiming to reduce the use of d4T. However, many individuals in resource-limited settings continue to use d-drugs because of their widespread availability and low cost; as such, an estimated 1.1 million individuals still initiated a d4T-based first-line antiretroviral regimen in 2011 [35, 36] .
Of the nonnucleoside reverse transcriptase inhibitors (NNRTIs), in particular, nevirapine (NVP) has been linked to hepatotoxicity as part of a systemic hypersensitivity reaction [1, 26, [37] [38] [39] . Compared with the suspected liver steatosis/fibrosis effect of d-drugs and other nucleoside reverse transcriptase inhibitors (NRTIs), the NNRTI class effect on the liver is of a hepatitis-like nature [1, 4, 26, [37] [38] [39] .
Among the protease inhibitors (PIs), in particular, atazanavir (ATV) may cause hyperbilirubinemia and cholecystolithiasis, whereas TPV-related hepatitis is expected in 10% of recipients [4, 40, 41] . Coinfection with viral hepatitis has been associated with increased plasma levels of PIs, but the clinical impact of coinfection on antiretroviral-related hepatotoxicity is unknown [42] .
Although most antiretroviral-related adverse liver effects are reported to be acute, mild and asymptomatic [3] , prospective investigations of long-term antiretroviral use and clinical manifestations of end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC) have not, as yet, been conducted in a large heterogeneous cohort setting. This analysis aimed to describe incidence rates, predictors and survival after ESLD/HCC with focus on the potential association with cumulative use of individual antiretrovirals, and, in particular, d-drugs, because of their high susceptibility to induce fibrosis. variables retained in multivariable models if they were significantly associated (P < 0.05) with the outcome in univariate models.
Methods

Study population
Subsequent models also considered adjustment for the latest viral load (fitted categorically) and CD4 þ cell count, both as time-updated covariates; these covariates were purposely not included in our primary analyses of antiretroviral associations, as they may lie on the causal pathway between antiretroviral exposure and ESLD/ HCC. Antiretroviral exposure was fitted cumulatively (per 5 years) as it was hypothesized that the risk of any adverse liver events would increase with longer exposure [44] . All antiretroviral exposures were considered, regardless of when they accrued -thus, individuals may already have accrued several years of exposure to some of the antiretrovirals prior to baseline; exposure then continued to accrue after baseline if the individuals continued to receive the drugs (or restarted them at a later point in time).
An investigation of the association between time since d-drug discontinuation and ESLD/HCC rates was conducted adjusting for cumulative exposure to each drug and other potential confounders. This allowed us to assess the potential for any increased risk of ESLD/HCC to be reversed after cessation of the drug.
All statistical analyses were carried out using SAS version 9.3 (Statistical Analysis Software, Cary, North Carolina, USA).
Results
Characteristics
A total of 45 544 individuals were followed in D:A:D since 1 February 2004 and were included in the analysis; these individuals were predominantly white (49.6%), men (73.5%) and had acquired HIV through sex between men, MSM (44.5%) ( Table 1 ). The median age was 40 [interquartile range (IQR) [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] years at baseline and the median CD4 þ cell count was 434 (IQR 282-621) cells/ml. During a median follow-up of years, a total of 319 ESLD/HCC events occurred (incidence rate 1.01/1000 PYFU, 95% confidence interval 0.90-1.12) of which 209 were ESLD and 110 HCC events. Overall, 157 (49.2%) of the ESLD/HCC events were identified through an ESLD form, 88 (27.6%) through a cancer form and the remaining 74 (23.2%) through a death form. The most common clinical manifestation of ESLD was hepatic encephalopathy grades III-IV (43.3%), followed by endoscopically verified variceal bleeding (27.4%), hepatorenal syndrome (14.6%) and liver transplantation (5.1%), whereas 9.6% had more than one manifestation at the same event date. The median age of individuals experiencing ESLD/HCC (at the time of the event) was 47 (IQR 42-52) years, the most common mode of HIV acquisition was IDU (53.6%), the median CD4 þ cell count was 266 (IQR 153-448) cells/ml and 72.4% were confirmed HCV positive and 19.8% with active HBV co-infection ( Table 1) . As 82.8% of all events occurred in individuals coinfected with viral hepatitis, the ESLD/HCC incidence rate was low in individuals without HCVor HBVevidence [0.12/1000 PYFU (95% confidence interval 0.07-0.16)] ( Table 2) . Although the ESLD/HCC incidence rate was similar for individuals with HIV/HCV and HIV/HBV coinfection, the number of individuals with HIV/HCV/ HBV was limited (data not shown).
Prognosis
The 319 individuals with ESLD/HCC were followed for a median of 0.23 (IQR 0.01-1.88) years after diagnosis, over which time 241 (75.6%) died. The median survival after an ESLD/HCC diagnosis was 0.27 years, whereas the 1-year mortality rate (Kaplan-Meier estimate) was 62.6%. After exclusion of 52 individuals diagnosed with ESLD/HCC at time of death, the median survival after an 1734 AIDS 2016, Vol 30 No 11 , however, only to the extent that would be expected on the basis of combining the effects of each drug when used separately, as there was no evidence of synergy between the two drugs in this model. There was no strong evidence to indicate that the associations between the two d-drugs and ESLD/HCC differed between individuals with and without viral hepatitis coinfection (P ¼ 0.50 for interaction between d4T and any hepatitis, P ¼ 0.09 for ddI and any hepatitis), although because of the small number of events in those without coinfection, the power to detect a significant interaction was extremely low.
Of the 18 676 persons on d4Tor ddI, 91.4% stopped their use at least once during follow-up, with only 18.4% of the PYFU in those exposed to d-drugs being current users. Those having previously stopped d-drugs had higher ESLD/HCC rates than those currently on d-drugs, an effect that only started to wane slightly after more than 6 years after cessation (Table 3) .
Discussion
This is the first large, prospective and long-term analysis to investigate incidence, outcomes and risk factors for clinically defined liver failure and cancer in HIV-positive persons with focus on the contribution of individual antiretrovirals.
We observed a relatively low overall incidence rate of ESLD/HCC in this large heterogeneous cohort of both HIV monoinfected and viral hepatitis coinfected persons. In comparison, a recent retrospective analysis from the Veterans Affairs cohort found that among antiretroviraltreated HIV/HCV coinfected persons, 7.4% experienced hepatic decompensation at 10 years [45] . This higher rate may, however, be explained by the conservative ESLD/ HCC criteria in D:A:D, and by the inclusion of ascites in the definition of hepatic decompensation, which was not originally included in the D:A:D definition as it may also be seen in other noncirrhotic liver disease-related conditions [46] . The prognosis following ESLD/HCC was poor with a median survival of only 0.27 years. This observation calls for an increased awareness of ESLD/HCC risk factors and management. The recent introduction of effective directacting agents (DAAs) for treatment of HCV will likely change the ESLD/HCC incidence and survival over the years to follow.
Antiretroviral risk factors of end-stage liver disease and hepatocellular carcinoma
We identified cumulative use of ddI, d4T, TDF and APV to be independently associated with an increased rate of ESLD/HCC development, whereas use of FTC and NVP were associated with decreased rates.
The association between cumulative ddI and d4T use and excess ESLD/HCC incidence builds on the observations of a number of relatively small studies of HIVmonoinfected and viral hepatitis coinfected individuals using various biomarkers of liver failure [5, 14, 18] . A recent retrospective study among 146 HIV/HCV coinfected persons found that each additional year of use of these drugs was associated with a 50% increase in the odds of progressing one or more grades on the Brunt score [15] . Similarly, a subanalysis among 205 HIV/HCV coinfected persons randomized to two types of anti-HCV treatment found that ddI use was associated with threefold higher odds of histologically verified fibrosis [16] , and a European cross-sectional study of 671 HIV/HCV coinfected persons found that a median use of ddI exceeding 5 months increased the odds of severe liver fibrosis by 70% [13] .
The incidence rate of ESLD/HCC among those who had been exposed to ddI and/or d4T was higher among individuals who had discontinued the drugs, than among those currently receiving them. This may reflect the fact that those at highest underlying risk of ESLD/HCC may be most likely to stop the d-drugs. Several mechanisms have been suggested for d-drug hepatotoxicity including inhibition of the mitochondrial DNA polymerase gamma and the mitochondrial respiratory chain with resulting oxidative damages and lactic acidosis [3, 16, 47, 48] , hepatic steatosis (microvascular and macrovascular), hepatocellular damage and ultimately development of cirrhosis [13, 15] .
The observed higher incidence of ESLD/HCC did not begin to decrease until 6 years after cessation of ddI and d4T use, suggesting that exposure to the drugs may have caused irreversible tissue damage. This finding is in accordance with work from Scourfield et al. [34] who found that the adverse liver effects of ddI developed late and after use of the drug was discontinued. These In contrast to the associations seen with ddI and d4T, the observed association between ESLD/HCC and TDF was unexpected. As TDF may be used preferentially among those with HBV coinfection, it may not be surprising that we see an increased rate of hepatotoxicity in those exposed to this drug [1, 49] . Importantly, however, the TDF association remained unchanged after stratifying [50] . Finally 3TC, which is also used to treat HBV infection, although less often because of a lower genetic resistance barrier, did not remain statistically significantly associated with ESLD/HCC in adjusted models. Use of FTC, which is commonly coprescribed with TDF (68% of those currently on TDF were also on FTC) was further independently associated with a lower ESLD/HCC risk and further argues against the hypothesis that our observed TDF association simply reflects a higher rate of unreported HBV infection. Outside the D:A:D study, only a few studies, predominantly smaller case reports, have reported a positive association between liver impairment and TDF [49, 51, 52] . This TDF association does, however, seem to be robust in D:A:D and is related to several liver outcomes, calling for confirmation in other large studies. No biological mechanism is currently known for TDF to cause ESLD/HCC, but the effect may relate to the development of mitochondrial toxicity in hepatocytes as described in renal tubular cells [53] , and steatosis is described in the TDF product information [54] . Our results also call for further investigations in mechanistic studies.
Based on the literature, if anything, one would have expected use of NVP to be associated with increased risk of ESLD/HCC [1, 26, [37] [38] [39] . Instead, we observed a lower rate of ESLD/HCC associated with cumulative NVP use. This may reflect the fact that NVP may only contribute to acute, but not more advanced and chronic stages of liver disease, but may also reflect some degree of confounding by indication with NVP not being prescribed to high-risk individuals, or being discontinued in those who experience liver enzyme elevations after starting the drug.
Elevated levels of transaminases are a common adverse effect of APV, although a recent small study did not identify a safety concern with long-term use [55, 56] . A recent mechanistic study further found some evidence to support an anti-HCC effect of APV [57] . APV may, because of its use in calculating dose recommendations for various levels of liver impairment, preferably have been used in individuals with liver impairment and the use is currently limited [58] . No other statistically significant associations were observed for cumulative use of other protease inhibitors including ATV. This suggests that from a clinical liver endpoint perspective, the commonly used PIs can be safely used in HIV-positive individuals over longer periods of time, a finding that is in accordance with other recent studies using biomarker-defined hepatotoxicity. Of note, use of TPV and darunavir are still too limited to allow for robust statistical analyses in D:A:D. Furthermore, our analysis did not consider any impact of DAAs for treatment of HCV, where there are known drug-drug interactions with PIs, as the use of DAAs in D:A:D is still extremely low.
Limitations
The limitations of this analysis should be acknowledged and include the lack of a systematic collection on information on alcohol consumption. However, the associations observed with use of ddI, d4T, TDF, APV, NVP and FTC are unlikely to be confounded by alcohol usage, as the choice of ART including these antiretrovirals is unlikely to be modified by the clinician's knowledge of the individuals alcohol consumption. A high number of antiretrovirals were included in the analysis, hence we cannot rule out that findings may be a result of multiple testing and the possibility of false-positive errors.
Confounding by indication cannot be ruled out for a number of the included antiretrovirals, in particular, as discussed, APV and NVP. Finally, nonantiretroviral hepatotoxic treatment, such as antituberculosis treatment with isoniazid and rifampicin, or sulphonamides used to treat pneumocystis pneumoni, may represent unmeasured confounding although adjustment for previous AIDS events did not change any of the observed antiretroviral associations.
Conclusion
While the ESLD/HCC incidence was relatively low in this large heterogeneous cohort, and predominantly seen in individuals with viral hepatitis coinfection, the prognosis following a diagnosis was very poor. Cumulative use of ddI, d4T, TDF and APV was independently associated with increased rates of ESLD/HCC, whereas use of NVP and FTC was associated with lower rates. There was limited evidence for reversibility of ESLD/ HCC risk upon cessation of d-drugs, and intensified monitoring of liver function and avoidance of hepatotoxic compounds should hence be considered among all with longer-term current or prior d-drug exposure. The unexpected, and viral hepatitis independent, TDF association calls for further investigations, whereas use of d-drugs should be avoided, where there are alternatives available. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above.
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